S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
An Unusual Way to Invest in Gold (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
An Unusual Way to Invest in Gold (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
An Unusual Way to Invest in Gold (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
An Unusual Way to Invest in Gold (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

$113.74
+0.63 (+0.56%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$113.01
$114.86
50-Day Range
$96.00
$117.10
52-Week Range
$89.04
$129.29
Volume
477,100 shs
Average Volume
765,560 shs
Market Capitalization
$11.11 billion
P/E Ratio
65.75
Dividend Yield
N/A
Price Target
$128.52

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
13.0% Upside
$128.52 Price Target
Short Interest
Healthy
2.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.78mentions of Neurocrine Biosciences in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$3.24 M Sold Last Quarter
Proj. Earnings Growth
121.36%
From $2.20 to $4.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

78th out of 961 stocks

Biological Products, Except Diagnostic Industry

7th out of 159 stocks


NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Price History

NBIX Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $137.00
Neurocrine Biosciences' (NBIX) Neutral Rating Reaffirmed at Mizuho
Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright
H.C. Wainwright Sticks to Its Buy Rating for Neurocrine (NBIX)
Neurocrine (NBIX) Receives a Buy from Goldman Sachs
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
8/01/2023
Today
9/25/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$128.52
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+13.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

Net Income
$154.50 million
Pretax Margin
13.99%

Debt

Sales & Book Value

Annual Sales
$1.49 billion
Cash Flow
$1.78 per share
Book Value
$17.76 per share

Miscellaneous

Free Float
93,160,000
Market Cap
$11.11 billion
Optionable
Optionable
Beta
0.46
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 65)
    CEO & Director
    Comp: $1.9M
  • Mr. Matthew C. Abernethy (Age 43)
    Chief Financial Officer
    Comp: $1.04M
  • Mr. Darin M. Lippoldt Esq. (Age 57)
    Chief Legal Officer & Corp. Sec.
    Comp: $921.01k
  • Mr. Kyle W. Gano Ph.D. (Age 50)
    Chief Bus. Devel. and Strategy Officer
    Comp: $921.52k
  • Dr. Eiry Wyn Roberts M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.04M
  • Dr. Jude Onyia Ph.D. (Age 59)
    Chief Scientific Officer
  • Jane Sorensen
    Head of Investor Relations
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 57)
    Chief HR Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 58)
    Chief Commercial Officer
  • Mr. David Warren Boyer (Age 44)
    Chief Corp. Affairs Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

21 brokers have issued 12-month price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $154.00. On average, they expect the company's stock price to reach $128.52 in the next year. This suggests a possible upside of 13.0% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX shares have decreased by 4.8% and is now trading at $113.74.
View the best growth stocks for 2023 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Tuesday, August, 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.18. The firm earned $452.70 million during the quarter, compared to analyst estimates of $448.29 million. Neurocrine Biosciences had a net margin of 10.54% and a trailing twelve-month return on equity of 10.39%.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.81%), State Street Corp (4.05%), Bellevue Group AG (2.68%), Renaissance Technologies LLC (1.68%), Bank of New York Mellon Corp (1.63%) and Geode Capital Management LLC (1.56%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $113.74.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $11.11 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.73 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 1,200 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -